Show simple item record

dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorFalk, Sally
dc.contributor.authorAshcroft, Linda
dc.contributor.authorBewley, Michelle
dc.contributor.authorLorigan, Paul C
dc.contributor.authorWilson, E
dc.contributor.authorGroom, N
dc.contributor.authorSnee, M
dc.contributor.authorFournel, P
dc.contributor.authorCardenal, F
dc.contributor.authorBezjak, A
dc.contributor.authorBlackhall, Fiona H
dc.date.accessioned2016-03-03T14:43:31Zen
dc.date.available2016-03-03T14:43:31Zen
dc.date.issued2016en
dc.identifier.citationProtocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. 2016, 6 (1):e009849 BMJ Openen
dc.identifier.issn2044-6055en
dc.identifier.pmid26792218en
dc.identifier.doi10.1136/bmjopen-2015-009849en
dc.identifier.urihttp://hdl.handle.net/10541/600554en
dc.description.abstractConcurrent ONce-daily VErsus twice-daily RadioTherapy (CONVERT) is the only multicentre, international, randomised, phase III trial open in Europe and Canada looking at optimisation of chemoradiotherapy (RT) in limited stage small cell lung cancer (LS-SCLC). Following on from the Turrisi trial of once-daily versus twice-daily (BD) concurrent chemoradiotherapy, there is a real need for a new phase III trial using modern conformal RT techniques and investigating higher once-daily radiation dose. This trial has the potential to define a new standard chemo-RT regimen for patients with LS-SCLC and good performance status.
dc.language.isoenen
dc.rightsArchived with thanks to BMJ openen
dc.titleProtocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.en
dc.typeArticleen
dc.contributor.departmentManchester Academic Health Science Centre, Institute of Cancer Sciences, Manchester Cancer Research Centre (MCRC), The University of Manchester, Manchester, UK Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalBMJ Openen
refterms.dateFOA2020-04-03T15:07:31Z
html.description.abstractConcurrent ONce-daily VErsus twice-daily RadioTherapy (CONVERT) is the only multicentre, international, randomised, phase III trial open in Europe and Canada looking at optimisation of chemoradiotherapy (RT) in limited stage small cell lung cancer (LS-SCLC). Following on from the Turrisi trial of once-daily versus twice-daily (BD) concurrent chemoradiotherapy, there is a real need for a new phase III trial using modern conformal RT techniques and investigating higher once-daily radiation dose. This trial has the potential to define a new standard chemo-RT regimen for patients with LS-SCLC and good performance status.


Files in this item

Thumbnail
Name:
Protocol for the CONVERT trial ...
Size:
791.5Kb
Format:
PDF
Description:
Main article

This item appears in the following Collection(s)

Show simple item record